Ryan Scott

Articles

Zanubrutinib Improves PFS in Treatment-Naive CLL/SLL, Regardless of Complex Karyotypes

December 20th 2023

Paolo Ghia, MD, PhD, describes the various cohorts of the SEQUOIA study, expands on outcomes from a biomarker subgroup analysis with zanubrutinib vs bendamustine plus rituximab, and more.

ctDNA Could Aid in Treatment Escalation and De-escalation Decisions in Kidney Cancer

December 19th 2023

Alan Tan, MD, discusses how utilizing circulating tumor DNA may provide valuable insight into when to escalate vs de-escalate treatment for patients with renal cell carcinoma.

Zanubrutinib Continues to Provide PFS Benefit Vs Ibrutinib in Relapsed/Refractory CLL/SLL

December 19th 2023

Jennifer R. Brown, MD, PhD, discusses the clinical implications of the ALPINE study and highlights a subgroup analysis of acquired mutations in patients with chronic lymphocytic leukemia, demonstrating which mutations were associated with resistance to covalent BTK inhibitors.

SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis

December 18th 2023

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer

December 18th 2023

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Lutetium Lu 177 Vipivotide Tetraxetan Addresses Unmet Need in Taxane-Naive mCRPC

December 18th 2023

Oliver Sartor, MD, discusses the significance of the data with lutetium Lu 177 vipivotide tetraxetan in the open-label, multicenter randomized study, highlights potential next steps with this approach, and expands on unique adverse effects to be aware of when treating patients with this drug.

Neoadjuvant KN026 Plus Docetaxel Demonstrates Early Activity in HER2+ Breast Cancer

December 14th 2023

The novel bispecific antibody KN026 and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive early or locally advanced breast cancer.

Obesity May Contribute to Biological Differences in Breast Cancer Tumors

December 8th 2023

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

Immune-Targeted Therapy Continues to Fall Short in Ovarian Cancer

December 1st 2023

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Hematologists Dive into the Current Treatment Landscape

November 28th 2023

Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.

EMA Validates Application for Epcoritamab in Relapsed/Refractory Follicular Lymphoma

November 27th 2023

The European Medicines Agency has validated a type II application for the investigational T-cell engaging bispecific antibody epcoritamab-bysp for patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of therapy

Ongoing Research Aims to Better Define Role of ASCT in Myeloma

November 27th 2023

Marc J. Braunstein, MD, PhD, discusses the current role of autologous stem cell transplant for patients with multiple myeloma, highlighted the key factors used to determine patient eligibility, and detailed ongoing research centered around autologous stem cell transplant.

Fruquintinib Approval Highlights Strides Made in mCRC Armamentarium in 2023

November 22nd 2023

Cathy Eng, MD, FACP, FASCO, discusses the implications of the fruquintinib approval, as well as other key clinical trial data and regulatory decisions within the colorectal cancer realm in 2023; the importance of early molecular testing in this patient population; and the continued importance of enrolling eligible patients onto clinical trials.

Dato-DXd Plus Durvalumab Elicits Durable Responses in Metastatic TNBC Regardless of PD-L1 Status

November 22nd 2023

Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.

Overcoming Resistance Mutations Is a Focus for Novel Therapies in R/R CLL

November 21st 2023

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

Ongoing Research Aims to Bring Bispecific Antibodies to Earlier Settings and Novel Combinations in Myeloma

November 21st 2023

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.

Pelabresib Plus Ruxolitinib Improves Spleen Volume Reduction in JAK Inhibitor-Naive Myelofibrosis

November 21st 2023

Treatment with the combination of pelabresib and ruxolitinib led to a statistically significant and clinically meaningful improvement in spleen volume reduction vs placebo plus ruxolitinib in patients with JAK inhibitor-naive myelofibrosis, meeting the primary end point of the phase 3 MANIFEST-2 trial.

FDA Approval Sought for Amivantamab Plus Chemo in EGFR+ Advanced NSCLC Following Osimertinib Progression

November 20th 2023

A supplemental biologics license application seeking the approval of amivantamab in combination with platinum-based chemotherapy for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 19 deletions has been submitted to the FDA.

KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/Refractory Solid Tumors

November 17th 2023

The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

November 16th 2023

Gaby Hobbs, MD, discusses how research into the biology of myelofibrosis has propelled the development of novel therapies for this patient population and highlights the role that biomarkers play in the diagnosis, prognosis, and treatment response evaluation for these patients.